Ondansetron, a new antiemetic therapy for oncology. An overview.
The nausea and emesis associated with chemotherapy still constitute an important problem in anticancer treatment. The new specific 5-HT3 receptor antagonists appear to be effective against vomiting induced by chemotherapy and radiation. An overview is given of the current theories on the physiology of emesis and the available literature on ondansetron (GR38032F) as an antiemetic.
Lip
H
H
Dept. of Anaesthesiology, Sophia Ziekenhuis, Zwolle, The Netherlands.
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D017294:Ondansetron; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology
D000932:Antiemetics; D000970:Antineoplastic Agents; D007093:Imidazoles; D017294:Ondansetron